ChromaDex (NASDAQ:CDXC) Shares Cross Above 200-Day Moving Average of $2.47

ChromaDex Co. (NASDAQ:CDXC)’s share price crossed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $2.47 and traded as high as $2.85. ChromaDex shares last traded at $2.65, with a volume of 472,368 shares.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. StockNews.com initiated coverage on ChromaDex in a research report on Sunday, March 3rd. They issued a “strong-buy” rating for the company. HC Wainwright reissued a “buy” rating and set a $6.00 price target on shares of ChromaDex in a research report on Thursday, May 9th. Finally, Roth Mkm restated a “buy” rating and issued a $6.00 target price on shares of ChromaDex in a research note on Wednesday, June 12th.

ChromaDex Trading Up 3.0 %

The firm’s 50-day simple moving average is $3.16 and its two-hundred day simple moving average is $2.48. The company has a market cap of $206.22 million, a PE ratio of -54.60 and a beta of 1.89.

ChromaDex (NASDAQ:CDXC) last announced its quarterly earnings data on Wednesday, May 8th. The company reported ($0.01) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.02. The firm had revenue of $22.15 million for the quarter, compared to analyst estimates of $22.35 million. ChromaDex had a negative net margin of 4.24% and a negative return on equity of 12.61%. As a group, analysts predict that ChromaDex Co. will post -0.02 EPS for the current year.

Institutional Trading of ChromaDex

Several institutional investors and hedge funds have recently bought and sold shares of CDXC. Perritt Capital Management Inc. acquired a new position in ChromaDex during the first quarter valued at $139,000. Lazard Asset Management LLC acquired a new stake in ChromaDex in the first quarter valued at approximately $43,000. Acadian Asset Management LLC purchased a new stake in ChromaDex in the 1st quarter worth $67,000. SG Americas Securities LLC acquired a new position in shares of ChromaDex during the 1st quarter worth about $54,000. Finally, Tieton Capital Management LLC boosted its stake in shares of ChromaDex by 18.8% in the fourth quarter. Tieton Capital Management LLC now owns 2,913,675 shares of the company’s stock worth $4,167,000 after acquiring an additional 461,692 shares during the last quarter. 15.41% of the stock is currently owned by institutional investors and hedge funds.

ChromaDex Company Profile

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.